US 7,468,185 B2
	Vaccine for periodontal disease
John Morgan Hardham, Gales Ferry, Conn. (US); Kendall Wayne King, Waterford, Conn. (US); Rajendra Krishnan, Portage, Mich. (US); Kimberly Jean Dreier, Oakdale, Conn. (US); and David Ross McGavin, Portage, Mich. (US)
Assigned to Pfizer Inc., New York, N.Y. (US)
Filed on Dec. 18, 2002, as Appl. No. 10/323,069.
Claims priority of provisional application 60/342999, filed on Dec. 21, 2001.
Prior Publication US 2003/0228328 A1, Dec. 11, 2003
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/02 (2006.01); C07H 21/04 (2006.01); C12P 21/02 (2006.01); C12N 1/12 (2006.01); C07K 14/195 (2006.01)

U.S. Cl. 424—190.1  [424/50; 435/69.1; 435/252.3; 435/320.1; 530/350; 536/23.7]

4 Claims

1. A vaccine for treating or preventing periodontal disease in dogs or cats comprising an immunologically effective amount of an inactivated pigmented anaerobic bacteria and a pharmaceutically acceptable carrier, wherein said pigmented anaerobic bacteria is Porphyromonas. gulae and said bacteria is capable of colonizing the oral cavity of dogs or cats and causes, either directly or in combination with other pathogenic agents, periodontal disease in dogs or cats and wherein its 16S rRNA DNA comprises the nucleic acid sequence, SEQ ID NO: 86.